HDAC9 and neoplasm: In addition to the above-mentioned drug hits, the response rate of INF_R_1288_r1-derived tumors also improved upon the treatment with HDAC inhibitor panobinostat (3 of 8 tumors show at least a 30% decrease in tumor volume) (Figure 5a).